EP1931356A2 - Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone - Google Patents

Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone

Info

Publication number
EP1931356A2
EP1931356A2 EP06805927A EP06805927A EP1931356A2 EP 1931356 A2 EP1931356 A2 EP 1931356A2 EP 06805927 A EP06805927 A EP 06805927A EP 06805927 A EP06805927 A EP 06805927A EP 1931356 A2 EP1931356 A2 EP 1931356A2
Authority
EP
European Patent Office
Prior art keywords
butyric acid
acid ester
oligosaccharides
products
butyrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06805927A
Other languages
German (de)
English (en)
Inventor
Alireza Haji Begli
Michael Klingeberg
Jörg Kowalczyk
Gunhild Kozianowski
Stephan Theis
Wolfgang Wach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suedzucker AG
Original Assignee
Suedzucker AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suedzucker AG filed Critical Suedzucker AG
Publication of EP1931356A2 publication Critical patent/EP1931356A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the invention relates to butyric esters or butyrate esters of carbohydrates and carbohydrate polyols and their use as butyric-carrier and butyrate source for the gastrointestinal tract, in particular for the prevention and treatment of diseases of the gastrointestinal tract, especially of the colon.
  • the C 4 acid butyric acid (butyrate) in the colon of a mammal is generally derived from the fermentation of undigested dietary constituents, especially undigested carbohydrates, by the microbial flora of the colon.
  • Butyrate is the dominant source of energy for epithelial cells, particularly epithelial cells of the posterior colon.
  • butyrate also affects physiological functions such as cellular proliferation, differentiation and apoptosis, plays a central role as a growth factor for a healthy intestinal epithelium and in the maintenance of the mucosal barrier in the colon.
  • Butyrate contributes to the detoxification of possible mutagenic metabolites in the colon and counteracts oxidative stress, for example by inducing gene expression of protective proteins such as intestinal glutathione-S-transferase or the inhibition of ornithine decarboxylase. Furthermore, butyrate acts to control the induction of specific genes of cell cycle regulation, antibacterial peptides and signaling cascades.
  • Ulcerative colitis is estimated to be about 0.1%, as is the prevalence of Crohn's disease. The prevalence of irritable bowel syndrome is much higher at 1, 1%. The provision of butyrate in the colon is considered in these diseases as a suitable measure for remission maintenance as well as to improve wound healing, for example after intestinal surgery (Wumbleters Reifen et al., 2000). Also for colorectal carcinoma, the incidence of which is estimated at about 0.1%, as well as for carcinogenesis, butyrate is considered to be a significant protective factor.
  • butyrate formed in the fermentation can vary widely. It depends on the particular fermented carbohydrate. From various indigestible carbohydrates such as inulin, polydextrose, pectin or arabinogalactan little butyrate is formed but predominantly acetate, propionate and gases such as hydrogen, carbon dioxide and methane (Cummings et al., 2001).
  • butyrate Up to about 5 g / day of butyrate are considered to be preventative or therapeutically effective butyrate (Scheppach et al., 1992). According to Vernia et al. (2000) 4 g / day butyrate support the therapeutic effect of mesalazine (2.4 g / day) in the treatment of ulcerative colitis. This is an amount that can not be achieved by the fermen- tative breakdown of carbohydrates in the colon. For example, it is known that degradation of 30g / day fermentable substrate (dietary fiber, resistant starch, etc.) results in the formation of an average of 2.2g of butyrate (Wolin, 1981). Accordingly, only about 0.07 g of butyrate are formed per 1 g of known fermentable substrates.
  • Butyrate which is absorbed through the diet, is rapidly and completely absorbed in the small intestine and thus does not enter the large intestine (Schmitt et al., 1976).
  • free butyric acid is a generally sensory, taste or organoleptically unattractive substance and can not be used directly in foods or drinks.
  • Tributyrin triglyceride with 3 molecules of butyrate
  • the technical problem underlying the present invention is thus, above all, to provide means and measures in order to supply the large intestine therapeutically or preventively with sufficient butyrate quantities, especially by simple oral or enteral administration.
  • the technical problem is solved by the use of at least one Butterkladers or a mixture of at least two different Butterklad (Butterklareester mixture) as Butyratetti in the digestive tract of the human or animal see body, especially for the treatment and / or prevention of or against diseases of the stomach Intestinal tract, especially the anterior and / or posterior sections of the intestine, especially the large intestine, but especially the colon.
  • the butyric esters are esters of at least one carbohydrate, esters of at least one carbohydrate polyol and / or esters of mixtures of carbohydrate and carbohydrate polyol.
  • the butyric acid ester (s) used according to the invention are preferably administered orally or enterally, especially in micro- and / or macroencapsulated form.
  • Butane acid with carbohydrates and / or with carbohydrate polyols, ie saccharides or saccharide alcohols, can be used as a small intestinal-stable carrier for butyrate.
  • Certain butyric esters of carbohydrates and polyols are surprisingly stable in passage through the stomach and small intestine. They are caused by enzymes present in the small intestine, such as pasen and esterases are not degraded, and there is no butyrate released from it. The bound butyrate thus escapes the digestion and absorption in the small intestine.
  • the butyric acid esters used according to the invention are unchanged in the large intestine. There, the esterified butyric acid is then released from the butyric acid esters by the microbial activity of colon-based bacteria.
  • the butyric acid release in the large intestine is surprisingly higher in pure butyric acid derivatives than in the mixed acid derivatives of acetate and butyrate;
  • the fermentation of sorbitol per 1 g of substrate produces only about 0.3 g of butyrate, and the fermentation of the unesterified carbohydrate polyols isomalt and xylitol results in about 0.2 g and about 0.3 g, respectively butyrate.
  • degrading other fermentable carbohydrates rate of resistant starch is about 0.2 g of butyrate per 1 g of substrate.
  • tributyrylsorbitol or tetrabutyrylsorbitol according to the invention surprisingly, about 0.7 g of butyrate are liberated per 1 g of substrate.
  • butyrate per 1 g of substrate are also formed from tributyrylxylitol or tetrahydrobyxylitol which is preferred according to the invention.
  • butyric acid esters according to the invention surprisingly and advantageously about 3 times more butyrate is formed in comparison with non-esterified substrates.
  • the butyric esters according to the invention "deliver", a) due to
  • the butyric acid esters of carbohydrate polyols used in accordance with the invention are particularly suitable for supplying the large intestine with the butyrate amounts of about 0.5 to 5 g / day required therapeutically or preventively. These butyrate amounts could already be achieved at a take up of from 0.7 to 7 g / day of butyric acid esters such as tri- and tetrabutyrylsorbitol as well as tri- and tetrabutylaryl. For the same amount of butyrate, it would be necessary to supply unesterified substrates by way of fermentative degradation of carbohydrates, such as resistant starch, in amounts of up to 70 g, that is, almost 10 times more substance.
  • the results of incubation experiments with colon bacteria in humans show that the butyric esters used according to the invention are surprisingly metabolized only slowly. That is, butyrate is released and formed over a long period of time, especially over more than 72 hours.
  • the butyric acid esters used according to the invention thus provide a continuous and a long-lasting source of butyrate in the colon.
  • the slow release ensures that butyric acid esters used according to the invention are present throughout the large intestine passage and thus also reach the rear colon regions.
  • sufficiently large amounts of butyrate are advantageously still available in the posterior regions of the colon, and can thereby develop prophylactic or therapeutic effects in those areas of the intestine where the inflammatory, infectious or malignant diseases occur most frequently.
  • the butyric acid ester used according to the invention preferably has a degree of substitution (DS) of 3 to 4. Also preferred are - depending on the field of application and starting compound - DS of 1, 2, 3, 4, 5, 6, 7, 8 and 9.
  • the butyric acid ester is partially esterified and preferably has a degree of esterification of 10 to 90%, 30 to 90 %, 40 to 80% and especially from 50 to 80%.
  • the carbohydrate or the carbohydrate polyol is a monosaccharide, disaccharide, oligosaccharide, polysaccharide. Preference is also given to mixtures of at least one carbohydrate and at least one
  • Carbohydrate polyol mannitol, sorbitol, xylitol, lactitol, maltitol, erythritol, isomalt, 1, 6-GPS, 1, 1-GPS, 1, 1-GPM, hydrogenated starch hydrolyzate, hydrogenated glucose syrup and / or a mixture thereof.
  • the carbohydrate polyol is a C 5 -PoIyOl and / or a C 6 polyol.
  • the carbohydrate polyol is a
  • the butyric acid ester used according to the invention is tributyrylsorbitol, tetrabutyrylsorbitol, tributyrylxylitol, tetrabutyrylxylitol, pentabutyrylisomalt or a mixture thereof and / or a mixture with other butyric acid esters.
  • Butyric acid isomalt esters are also distinguished by their less unpleasant taste, in comparison to other butyric esters used according to the invention, for example butyric acid sorbitol esters.
  • the invention also provides the use of mixed esters with butyrate and other short-chain alkanoic acids, preferably acetate.
  • the molar ratio of carbohydrate and / or carbohydrate polyol to acid or acid anhydride is generally from 1: 1 to 1:10, in particular from 1: 3 to 1: 6.
  • the esterification can be carried out in the presence of an acidic catalyst, such as tin oxalate respectively. Excess acid is then removed in a conventional manner.
  • a preferred object of the invention is the use of the above-characterized butyric acid ester for the prophylactic and / or therapeutic support of a healthy intestinal milieu and a healthy intestinal epithelium as well as for the treatment or prevention of diseases of the gastrointestinal tract of the human or animal body.
  • Such diseases are diseases associated with butyrate administration in the
  • Colon can be treated or prevented.
  • diseases associated with butyrate deficiency in the gastrointestinal tract diseases and conditions wherein butyrate contributes to the detoxification of potential mutagenic metabolites in the colon, diseases and conditions wherein butyrate oxidati- It counteracts stress, for example via the induction of gene expression of protective proteins such as intestinal glutathione-S-transferase or the inhibition of ornithine decarboxylase, diseases with a pathological, toxic or drug-related impairment or damage to the epithelial cells and colons of the posterior colon or the mucosal barrier in the large intestine, inflammation of the colon such as colitis or pseudomembranous colitis, chronic inflammatory bowel disease such as ulcerative colitis and Crohn's disease and irritable bowel syndrome, infections with clostridia, antibiotic-associated diarrhea, traveler's diarrhea, colorectal carcinoma.
  • the use according to the invention also provides remission maintenance and improvement of wound healing, for example after intestinal
  • the invention provides for the use of at least one of the butyric acid esters or a butyric acid ester mixture as an active ingredient, in particular as a therapeutic agent.
  • the butyric acid esters are preferably used in pharmaceuticals, pharmaceutical compositions, drug-like preparations.
  • the butyric acid esters are preferably used together with other pharmacologically suitable vehicles, additives and auxiliaries, such as lubricants, release agents, thickeners, emulsifiers, stabilizers, preservatives, lecithin, intensive sweeteners, sweeteners, colorants, flavorings, flavorings, coating materials and or
  • the use preferably takes place in solid and / or liquid, in particular in suspended or dissolved form.
  • suspension and solvent are preferably food-compatible solvents and emulsifiers in
  • the administration is preferably carried out - depending on the field of application - in the form of suspension, solution, emulsion, drops, juices, tablets, pills, capsules, troches, dragees, jellies, granules, powders, solution for injection or infusion, or in combinations thereof.
  • the use can also take place in a further, similarly suitable dosage form.
  • Especially preferred according to the invention is the administration of butyric acid esters in microencapsulated or macroencapsulated form into the human or animal body.
  • butyric acid esters can be administered in an organoleptically neutral form. Above all, a taste-neutral transport through the digestive tract is made possible.
  • at least one butyric acid ester is present in micro- and / or macroencapsulated form.
  • the encapsulation allows an improved, especially delayed or uniformed and continuous release of Butterklareester at the target site in the gastrointestinal tract or large intestine.
  • Next can be extended by the encapsulation of the application area; It is possible to prepare dry blends as well as well metered systems containing the butyric acid esters or mixtures according to the invention. Sensory negative effects of the butyric acid esters according to the invention, which are partly present, can be largely concealed by the encapsulation.
  • encapsulation of the butyric acid ester is understood to mean an encapsulation which is based primarily on the binding of the
  • Butyric acid ester to a carrier for example by adsorption, covalent or ionic bond or linkage with bi- or multi-functional reagents based.
  • the encapsulation is preferably also based on the inclusion of butyric acid esters in a matrix or membrane, for example by ionotropic gelation, polyelectrolyte complexes, symplexes, Cold gelation, formation of hydrocolloids, polymerization and / or solvent precipitation.
  • At least one butyric acid ester is encapsulated by inclusion process in at least one shell material.
  • Butyric acid ester is preferably at least one agent selected from alginates, agar-agar, agarose, pectins and pectinates, guar gum, chitosan, cellulose derivatives, starch derivatives, gum arabic, waxes, mono-, di- and triglycerides and other organic and inorganic substances used ,
  • polysaccharides, in particular pectinate and alginate are used for the encapsulation.
  • the forms of micro- and macroencapsulation of the butyric acid esters are preferably selected from spheres, cylinders, fibers or films, tablets, granules, powders, pills, lozenges, dragees and
  • At least one further protective layer of pure carrier material is preferably applied to complete the microencapsulation toward the outside.
  • a conventional coating material used in pharmacy for example hydroxypropylmethylcellulose (HPMC), is coated in a manner known per se. Particular preference is given to using a fluidized-bed agglomerator for fluidized-bed drying.
  • microencapsulated butyric acid esters is preferably carried out by means of atomizers, for example via the blow-off, electrostatic or vibratory method, by means of rotating disks and / or nozzles and jet cutters.
  • atomizers for example via the blow-off, electrostatic or vibratory method, by means of rotating disks and / or nozzles and jet cutters.
  • polysaccharides preferably pectinate, alginate, together with butyric acid ester or butyric acid ester mixture in prepared a solution and the solution obtained by means of atomizer, preferably by means of jet cutter dripped into a precipitation solution.
  • the precipitation solution used is preferably calcium chloride solution or magnesium chloride solution.
  • the resulting beads (spheres) have a diameter of less than 50 microns.
  • the beads are then dried in a fluidized bed dryer.
  • microencapsulation As a manufacturing method for a microencapsulation are further essentially known in the food industry methods such as spray drying, freeze-drying,
  • Fluidized bed drying, fluidized bed agglomeration or extrusion Fluidized bed drying, fluidized bed agglomeration or extrusion.
  • a syrup of a wall material for example, sugars, polyols and maltodextrin or other well crystallizing starch products, dried in conjunction with ButterTexreester or Butterklareester mixture by spraying the syrup, so that a solid, powdery or granular product wherein the butyric acid esters are encapsulated in the selected wall material.
  • wall material for example, a
  • wall material is introduced as a finely ground powder, for example sugar, polyol or maltodextrin, and then sprayed with an aqueous solution or suspension of the butyric acid ester or butyric acid ester mixture.
  • nozzles for spraying the solution or suspension above the fluidized bed topspray method
  • the nozzles are integrated in the bottom of the fluidized bed system (bottom spray method).
  • butyric acid esters is used as the sole source of butyrate, as the sole therapeutic or prophylactic active ingredient.
  • butyric acid ester is used together with at least one further butyrate source and / or at least one further active ingredient for the treatment or prevention of these diseases.
  • the use is preferably according to a treatment plan wherein a therapeutically and / or prophylactically effective dose is administered as a single dose or multiple doses, for example throughout the day, and preferably repeatedly administered over a given period of time. Preference is given to a dose of 0.7 to
  • the correspondingly multiplied daily dose may also be administered every 2, 3 or 4 days, preferably every 72 hours.
  • the dose is mainly from an adult human with 75 kg body weight, for children and for use in animals, the doses must be adjusted accordingly.
  • Combination therapy for example, for the treatment of Diseases such as a manifest colon carcinoma by means of chemotherapy (for example, with 5-Fluorourac ⁇ l) provided
  • the invention also provides a process for the treatment or prevention of the diseases, in particular of the gastrointestinal tract, comprising the, preferably oral or enteral,
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one of the above-characterizing butyric acid esters as at least one active ingredient as a medicament in the treatment or prevention of the diseases, in particular of the gastrointestinal tract, of the human or animal body
  • the invention also relates to the use of the above-characterized butyric acid ester as an active ingredient in food, food, semi-luxury foods and animal feeds and preferably for the manufacture of a medicament for the treatment or prevention of the diseases, in particular those of the gastrointestinal tract, of the human or animal body
  • foodstuffs are understood to mean, in particular, foods and semi-luxury foods as well as animal feeds, which in particular have a nutritional value and can serve the partial or complete nutrition of the human or animal body
  • Special foods such as baby foods, dietary foods, tube feeds for enteral nutrition and the like are understood to include animal feed, that is, all types of food for animals both in small animals and livestock, such as farm animals, sport horses, but also domestic, zoo and luxury animals, understood.
  • the food is present as a concentrate, as a raw material or as a semi-finished product.
  • foods also include drinks such as soft drinks, soft drinks, effervescent drinks, fruit juice drinks, lemonade, energy drinks, fruit juices, sweet must,
  • Fruit nectars, coffee, cocoa, milk, mineral drinks, tea and infused drinks and alcoholic beverages such as beer, Nährbier, mixed beer drinks, sour milk drinks (Kefir, Kumys u.a.), wine, fruit wine (cider, etc.) understood.
  • the invention also relates to a composition, in particular a food, feed or medicament containing at least one butyric acid ester or a butyric acid ester mixture used in accordance with the invention.
  • the composition contains at least one further constituent; this one is selected from:
  • Carbohydrate polyols preferably mannitol, sorbitol, xylitol, lactitol, maltitol, erythritol, isomalt, 1, 6-GPS, 1, 1-GPS, 1, 1-GPM, hydrogenated starch hydrolysates, hydrogenated glucose syrups and mixtures thereof;
  • Carbohydrates preferably monosaccharides, disaccharides, oligosaccharides, polysaccharides and mixtures thereof;
  • soluble and / or insoluble fiber preferably prebiotic and / or butyrogenic fiber, in particular resistant starch, modified starch, polydextrose,
  • Fructo-oligosaccharides Fructo-oligosaccharides, galactooligosaccharides, transgalactosylated oligosaccharides such as 6'-galactosyllactose or 4'-galactosyllactose lactulose, lactobionic acid, maltobionic acid, xylo-oligosaccharides, lacto-sucrose, malto-oligosaccharides, isomalto-oligosaccharides, gentio-oligosaccharides riden, glucosylsucrose, soybean oligosaccharides, chito-oligosaccharides, chitosan oligosaccharides, pectin, pectin oligosaccharides, condensed oligosaccharides, caramel products, galactomannan oligosaccharides, fucose-containing oligosaccharides, fucosederiv
  • short-chain fatty acids preferably butyric acid, propionic acid, acetic acid, lactic acid;
  • Butyric acid glycerol esters preferably glycerol tributyrate
  • acylated starch preferably butyrylated starch.
  • the composition contains a mixture of at least two of the abovementioned components, in particular of at least one carbohydrate and at least one carbohydrate polyol.
  • the invention also relates to such a foodstuff selected from:
  • Dairy products and dairy products such as cheese, butter, yoghurt, kefir, quark, sour milk, buttermilk, cream,
  • Condensed milk dried milk, whey, milk sugar, milk protein, milk mix, milk half fat, whey mixed or milk fat products or preparations; Milk fat products, mixed fat products, edible fats and edible oils;
  • Baked goods such as bread including biscuits and pastries, long-life baked goods, biscuit products and waffles;
  • Fruit products or preparations such as jams, marmalades, jellies, fruit preserves, fruit pulp, fruit pulp, fruit juices,
  • non-alcoholic drinks beverage bases and
  • Confectionery such as chocolates, hard caramels, soft caramels, chewing gum, dragees, fondant products, jelly products, licorice, marshmallows, flakes, dragées, comestibles, candied fruit, brittle, nougat
  • the invention also relates to a dietary special diet derived therefrom and enteral nutrition.
  • the invention also relates to a composition
  • a composition comprising at least one of the above-characterized butyric esters as animal feed such as pet food, Premixes for pet food, high-starch feed, concentrate and concentrated feed.
  • animal feed such as pet food, Premixes for pet food, high-starch feed, concentrate and concentrated feed.
  • prophylaxis and therapy of intestinal diseases can thus be made possible or supported in a way that is harmless to humans and animals.
  • the invention preferably provides the use of the butyric acid esters or mixtures thereof in enteral nutrition products and as a nutritional supplement or nutritional supplement.
  • FIG. 1 shows a diagram of the digestibility of various butyric acid xylitol
  • FIG. 2 is a graph of butyrate formation during in vitro fermentation with intestinal bacteria as a function of intestinal bacteria
  • Example 8 In Vitro Digestibility of Butyric Acid Esters of Carbohydrates and Carbohydrate Polyols
  • Carbohydrate polyols the following butyric acid esters were incubated with lipases and esterases from the pancreas and small intestine:
  • Tri buty ry I-Xy I it b. Tetrabutyryl xylitol c. Pentabutyryl xylitol d. Tributyryl sorbitol e. Tetrabutyryl sorbitol f. Tetrabutyryl diacetyl sorbitol g. Hexabutyryl sorbitol h. Pentabutyryl isomalt i. Heptabutyryl-diacetyl isomalt j. Octabutyryl isomalt Enzyme preparation from the small intestine mucosa
  • Small intestine esterases were isolated from porcine small intestine. For this purpose, an 18 m long small intestine of a freshly slaughtered pig was divided into 6 x 3 m sections, the mucosa of the individual
  • tributyrin control substance
  • butyric acid ester 20 mg were emulsified together with 4 mg of taurocholic acid in 1680 ⁇ l of 100 mM phosphate buffer, pH 7.5, with 220 ⁇ l of a 0.06% pancreatin solution and 100 ⁇ l of mucosal supernatant with esterase activity
  • control tributyrin was maximized under the incubation conditions, i. split to the level of Monobutyrats.
  • the fully esterified polyols hexabutyryl sorbitol, tetrabutyryldiacetyl sorbitol, octabutyryl isomalt and heptabutyryl diacetyl isomalt
  • pentabutyryl isomalt and tributyryl sorbitol were found to be resistant to enzymatic degradation. From tetrabutyryl sorbitol or tri-, tetra- and pentabutyryl-xylitol were 10.7-22.4% Butyrate released.
  • the results show that butyric acid esters of carbohydrate polyols were not or only slightly hydrolyzed during the passage of the small intestine and were therefore stable to the small intestine.
  • the acid stability in the course of the gastric passage was determined by incubation at pH 2.0 for 3.5 h at 37 0 C.
  • Vitamin solution (according to DSM 141) 0.5 ml / l
  • Cysteine / HCl was added as a reducing agent, inoculated. Hungate tubes were incubated with shaking at 37 ° C. for 72 h, sampled at different time points and assayed for short-chain fatty acids, lactic acid and pH. The extent of metabolism of the test substances was determined by determining the release of butyrate.
  • Tetrabutyryl diacetyl sorbitol 100% 0.3 1, 0
  • Hexabutyryl sorbitol was less metabolized by the intestinal bacteria than tri- or tetrabutyryl sorbitol, as evidenced by the low butyrate formation of 0.2 g butyrate / g substrate.
  • Fermentation of intestinal bacterial tetrabutyryl xylitol resulted in butyrate binding of 0.7 g butyrate / g substrate versus 0.3 g on fermentation of the unesterified xylitol. This value corresponds to a more than two-fold increase in butyrate formation. Also from
  • butyric acid esters of carbohydrate polyols in in vitro fermentation experiments with human intestinal bacteria, butyrate formation can be increased more than 3-fold over that of butyrate formation which can be achieved by fermentation of unesterified carbohydrates or resistant starch.
  • Butyric acid esters of carbohydrates or carbohydrate polyols are suitable as small intestine-stable butyrate carriers for the large intestine, with tributyryl sorbitol, tetrabutyryl sorbitol and tetrabutyryl xylitol being particularly suitable because of their high butyrate formation.
  • Example 12 Sodium alginate encapsulation of tetrabutyryl sorbitol
  • Jet cutter dripped into a 100 mmol / l CaCl 2 solution. It created beads with a diameter smaller than 50 microns. The beads were left in the solution for 2 hours for postcrosslinking, then sieved off and washed with water. The beads may be wet or used after drying in a fluid bed dryer.
  • Example 14 Fluidized bed agglomeration
  • 5 kg of finely ground isomalt ST are initially charged and fluidized in a fluidized-bed agglomerator as wall material (particle size 90% ⁇ 50 ⁇ m), followed by 1200 g of a spray solution consisting of a mixture of di-, tri- and tetrabutyrylsorbitol (800 g of ester and 400 g of water).
  • the spray solution is then changed and 500 g of a 20% isomalt solution are applied as an outer layer structure by spraying
  • the product is after-dried to a water content of 5.4%.
  • vanilla flavor 5 g.
  • Example 17 Milk products and products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne un ester d'acide butyrique ou un ester de butyrate d'hydrate de carbone et de polyols d'hydrate de carbone et leur utilisation en tant que support pour du butyrate et une source de butyrate dans le traitement du tractus estomac-intestins, permettant en particulier de prévenir et de traiter des maladies du tractus estomac-intestins, de préférence du gros intestin.
EP06805927A 2005-09-28 2006-09-28 Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone Withdrawn EP1931356A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005046237A DE102005046237A1 (de) 2005-09-28 2005-09-28 Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
PCT/EP2006/009436 WO2007036363A2 (fr) 2005-09-28 2006-09-28 Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone

Publications (1)

Publication Number Publication Date
EP1931356A2 true EP1931356A2 (fr) 2008-06-18

Family

ID=37806810

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06805927A Withdrawn EP1931356A2 (fr) 2005-09-28 2006-09-28 Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone

Country Status (6)

Country Link
US (1) US20080213341A1 (fr)
EP (1) EP1931356A2 (fr)
JP (1) JP2009509999A (fr)
CN (1) CN101316598A (fr)
DE (1) DE102005046237A1 (fr)
WO (1) WO2007036363A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040187A1 (it) * 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
WO2006012536A2 (fr) 2004-07-22 2006-02-02 Ritter Andrew J Procedes et compositions pour le traitement de l'intolerance au lactose
US20090297660A1 (en) * 2008-06-02 2009-12-03 Kraft Food Holdings, Inc. Cheese Products Containing Galacto-Oligosaccharides And Having Reduced Lactose Levels
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
PL2376077T3 (pl) 2009-01-12 2017-10-31 Biokier Inc Kompozycja i sposób leczenia cukrzycy
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
ES2600960T3 (es) 2009-02-24 2017-02-13 Ritter Pharmaceuticals, Inc. Formulaciones prebióticas y procedimientos de uso
CN101647517A (zh) * 2009-06-17 2010-02-17 新奥（厦门）农牧发展有限公司 丁酸盐或丁酸甘油脂与低聚果糖的复合物及其制法和在饲料添加剂中的应用
CN101647516A (zh) * 2009-06-17 2010-02-17 新奥（厦门）农牧发展有限公司 丁酸盐或丁酸甘油脂与膳食纤维的复合物及其制法和在饲料添加剂中的应用
EA201290158A1 (ru) 2009-09-23 2012-08-30 Биокиер, Инк. Композиция и способ лечения диабета
CA2790097A1 (fr) * 2010-03-05 2011-09-09 Ophthalmopharma Ag Chocolat nutraceutique ou produit compose a base de chocolat
EP2563372A4 (fr) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc Formulations prébiotiques et méthodes d'utilisation
CA2805445C (fr) * 2010-07-29 2018-05-01 Cosmo Technologies Ltd. Compositions pharmaceutiques et/ou alimentaires a base d'acides gras a chaine courte
IT1401309B1 (it) * 2010-08-03 2013-07-18 Cosmo Technologies Ltd Pharmaceuticals and/or dietary compositions based on short chain fatty acids. composizioni farmaceutiche e/o dietetiche a base di acidi grassi a corta catena.
GB201213629D0 (en) 2012-07-31 2012-09-12 Imp Innovations Ltd Compounds and their effects on appetite control and insulin sensitivity
WO2015084158A1 (fr) * 2013-12-06 2015-06-11 N.V. Nutricia Dérivé de pyrimidine et source d'acides gras destinés à être utilisés pour traiter la constipation
BE1023491B1 (nl) * 2015-10-06 2017-04-06 Nutri-Ad International Nv Voedingsadditief voor gevogelte
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
US20170127693A1 (en) * 2015-11-09 2017-05-11 Mead Johnson Nutrition Company Nutritional compositions containing butyrate and uses thereof
JP7097027B2 (ja) * 2016-08-10 2022-07-07 モナッシュ ユニバーシティ 自己免疫疾患の処置及び予防のための代謝物
JP2018158895A (ja) * 2017-03-22 2018-10-11 株式会社ダイセル 制御性ｔ細胞増加剤、食品、及び医薬
KR20200011972A (ko) * 2017-06-05 2020-02-04 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 멀티바이오틱제 및 이를 사용하는 방법
KR102082315B1 (ko) * 2018-05-08 2020-02-27 주식회사 비피도 부티릴 프락토올리고당을 포함하는 프리바이오틱스 조성물
EP3801489A4 (fr) * 2018-06-05 2022-03-30 Flagship Pioneering Innovations V, Inc. Agents actifs acylés et leurs procédés d'utilisation pour le traitement de troubles auto-immuns
CN109504713B (zh) * 2018-12-04 2022-05-17 齐鲁工业大学 利用拜氏梭菌制备高酯键腐植酸制剂的方法及应用
CN114760857A (zh) * 2019-12-05 2022-07-15 雀巢产品有限公司 膳食丁酸酯及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579547A (en) * 1966-12-16 1971-05-18 Scm Corp Carboxylic acid esters
JPS5089314A (fr) * 1973-12-14 1975-07-17
JPS61268192A (ja) * 1985-05-24 1986-11-27 Meito Sangyo Kk 糖類脂肪酸エステル化合物の製造法
US4959975A (en) * 1987-05-14 1990-10-02 Conserve, Inc. Heat pump system
FR2633929B2 (fr) * 1987-09-25 1995-05-24 Picardie Universite Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees
US4959466A (en) * 1988-01-25 1990-09-25 Arco Chemical Technology, Inc. Partially esterified polysaccharide (PEP) fat substitutes
WO1995009145A1 (fr) * 1993-09-30 1995-04-06 Eastman Chemical Company ESTERS DE GLYCEROL DE β-ACYLOXY BUTYRATES NUTRITIFS
DE4414138A1 (de) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Acylierte gamma-Cyclodextrine
FR2723096B1 (fr) * 1994-07-28 1996-10-18 Univ Picardie Esters associant les acides phenylacetique,3-phenyl-propionique, 4-phenyl-butyrique et n-butyrique au d-mannose, au xylitol et a leurs derives. applications comme medicaments
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US5763488A (en) * 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
IT1286510B1 (it) * 1996-11-29 1998-07-15 Cooperativa Centro Ricerche Po Esteri butirrici ad attivita' antiproliferativa e composizioni farmaceutiche che li contengono
AU2001279168A1 (en) * 2000-08-02 2002-02-13 Atossa Healthcare, Inc. Bimodal emulsions of taxanes and butyrate polyalcohol esters
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
DE10328180A1 (de) * 2003-06-16 2005-01-13 Südzucker AG Mannheim/Ochsenfurt Verwendung von Isomalt als Präbiotikum
US20060105962A1 (en) * 2004-11-14 2006-05-18 Robinson Robert O A Tonic to maintain intestinal flora

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007036363A2 *

Also Published As

Publication number Publication date
US20080213341A1 (en) 2008-09-04
DE102005046237A1 (de) 2007-04-05
WO2007036363A2 (fr) 2007-04-05
WO2007036363A3 (fr) 2007-10-11
JP2009509999A (ja) 2009-03-12
CN101316598A (zh) 2008-12-03
WO2007036363A8 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2007036363A2 (fr) Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone
KR101007512B1 (ko) 폴리덱스트로스를 사용한 면역계의 자극
EP1513942B1 (fr) Galactosyl-isomalte, son procede de preparation et son utilisation
DE102004035373B3 (de) Verbesserte kakaohaltige Mischungen
TWI391138B (zh) 含有纖維寡糖之組合物
WO2004112505A1 (fr) Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales
US20110177175A1 (en) Dietary fiber compositions
JP2003522822A (ja) 栄養性の改良されたイヌリン製品
JPH11335285A (ja) 整腸・便秘改善剤およびこれを含有する飲食物並びに動物用飼料
DE10262005B4 (de) Lebens-, Genuss-, Süßungs- und Arzneimittel, sowie Zusammensetzungen enthaltend kondensierte Palatinose in hydrierter Form
JP5442243B2 (ja) 腎障害抑制剤
TW200410702A (en) Agent for inhibiting rise in blood glucose level, agent for inhibiting body fat accumulation and edible material
JP2010053122A (ja) 脂質合成阻害剤
JP2018024619A (ja) 持久力向上剤
EP1616873B1 (fr) Agent regulateur de lipides et son utilisation
JP7217089B2 (ja) 血糖値上昇抑制剤及びこれを含んでなる経口組成物
JP2009120502A (ja) キトサン含有組成物
JP2010195734A (ja) フィチン酸、カルボン酸、および糖類の相乗効果による脂肪吸収抑制作用を有する組成物
JP7359415B2 (ja) ウレアーゼ阻害剤
JP2022068778A (ja) 腸内短鎖脂肪酸産生促進用組成物及びこれを含む飲食品
JP2007181441A (ja) コエンザイムｑ１０配合組成物の製造方法
KR0144566B1 (ko) 비피드균 증식 촉진제
JP2008063299A (ja) パイエル板形成誘導組成物
JP2006117626A (ja) コエンザイムｑ１０配合組成物の製造方法
DE102006001017A1 (de) Mittel zur Anwendung bei Blutzuckerstoffwechselstörungen einschließlich Diabetes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080428

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): DE FR GB

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB

17Q First examination report despatched

Effective date: 20091204

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130401